SCHEMBL5149368

SCHEMBL5149368

CCC(c1ccc(Nc2nccc3cnccc23)cc1)[C@H](NC1=CC(=O)C1(C)C)C(=O)O

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 1/20 0.34
ITGA4 P13612 1/20 0.34
KDR P35968 1/20 0.33
CSNK2A1 P68400 4/20 0.32
CSNK2A2 P19784 3/20 0.32
CSNK2B P67870 3/20 0.32
TRPV1 Q8NER1 2/20 0.32
HIPK2 Q9H2X6 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
HDAC3 O15379 1/20 0.30
HDAC1 Q13547 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5148458 0.91 KDR (0.32) ITGB1ITGA4KDRCSNK2A1CSNK2A2
SCHEMBL3832798 0.82 ITGB1 (0.38) ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B
SCHEMBL6131672 0.82 ITGB1 (0.38) ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B
SCHEMBL2982616 0.82 ITGB1 (0.51) ITGB1ITGA4
SCHEMBL5147512 0.80 FFAR1 (0.38) ITGB1ITGA4HIPK2
SCHEMBL5149503 0.79 TRPV1 (0.37) KDRCSNK2A1CSNK2A2CSNK2BTRPV1
SCHEMBL5264737 0.79 TRPV1 (0.37) KDRCSNK2A1CSNK2A2CSNK2BTRPV1
SCHEMBL3833596 0.79 MEN1 (0.32) ITGB1ITGA4CSNK2A1CSNK2A2CSNK2B
SCHEMBL5147804 0.78 EGFR (0.38) KDRCSNK2A1CSNK2A2CSNK2BTRPV1
SCHEMBL5149363 0.77 ITGB1 (0.43) ITGB1ITGA4KDRTRPV1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders UCB PHARMA S.A. (BE) 2007-07-19 US disclosed
EP-1780201-A2 PHENYLALANINE ENAMIDE DERIVATIVES POSSESSING A CYCLOBUTENE GROUP, FOR USE AS INTEGRIN INHIBITORS Celltech R&D Limited (GB) 2007-05-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167483-A1 2-[(2-Isopropylsulfanyl-3-oxo-spiro[3.5]non-1-en-1-yl)amino]-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoic acid; compounds can inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immuno or inflammatory disorders ITGB2, VCAM1, ITGB1 ITGB1 3/4885ITGA4 40/4885KDR 399/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.